Advanced Search

 

Study ID Status Title Patient Level Data
S2CT41 Completed Pre-emptive oral GR43175C treatment during a cluster headache period – (100mg tid for 7 days) – A double-blind, parallel group, placebo controlled study.
S2W20006 Completed A randomised, double-blind, placebo-controlled crossover study investigating the efficacy and safety of intermittent prophylactic treatment with oral naratriptan 1mg b.i.d. in women with pre-menstrual dysphoria. Study Listed on ClinicalStudyDataRequest.com
S2W30018 Completed An open study of the efficacy and tolerability of naratriptan in prophylactic treatment of pure menstrual migraine attacks.
S2W40010 Completed A randomised, double-blind, cross-over study to compare the patient preference of oral Naratriptan (Naramig) 2.5mg with Naproxen 500mg in patients dissatisfied with simple analgesics in the treatment of acute migraine.
S2W40012 Completed A randomized, double-blind, placebo-controlled, parallel group evaluation of oral naratriptan 1 mg twice daily asprophylactic treatment for menstrually-associated migraine.
S2W40016 Completed Efficacy and tolerability of oral sumatriptan 50mg, as acute treatment for mild to moderate migraine, in patients not responders to common analgesics or anti-inflammatories.
S2W40024 Completed A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of Oral Naratriptan 1mg TwiceDaily as Prophylactic Treatment for Menstrually-Associated Migraine. Study Listed on ClinicalStudyDataRequest.com
S2W40027 Completed An open-label evaluation of the long-term safety of oral naratriptan 1mg twice daily as short-term prophylactic treatment for menstrually-associated migraine. Study Listed on ClinicalStudyDataRequest.com
S2W40028 Completed A multicentre, open label trial to evaluate patient preference for Amerge® 2.5 mg in the acute treatment of migraine.
S2W40031 Completed A double-blind, randomised, parallel-group design, placebo-controlled study of the effects of naratriptan tablets 2.5mg in treatment of menstrually-associated migraine attack at a stage of mild pain.
S2WA1002 Completed A study to evaluate the pharmacokinetics of two doses of 1.0mg, 2.5mg and 5.0mg GR85548A tablets separated by 2 hours in healthy volunteers.
S2WA1003 Completed A study to determine the effect of food on the pharmacokinetics of oral naratriptan tablets in healthy female volunteers.
S2WA1004 Completed A comparative study of the pharmacologic effects of naratriptan, codeine and placebo in experienced psychoactive substance users.
S2WA1007 Completed A study to evaluate the pharmacokinetics and pharmacodynamics of oral naratriptan in migraine subjects.
S2WA1010 Completed A study to investigate the interaction of naratriptan and dihydroergotamine in healthy volunteers.
S2WA1011 Completed A study to investigate the interaction of naratriptan and ergotamine in healthy volunteers.
S2WA1012 Completed A study to investigate the pharmacokinetics of oral naratriptan in adolescent migraine patients outside a migraine attack.
S2WA3001 Completed A randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of four doses of oral naratriptan in the acute treatment of a single migraine attack.
S2WA3003 Completed A randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of oral naratriptan in the acute treatment of four migraine attacks.
S2WA3012 Completed A randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy, safety and tolerability of oral naratriptan in an adolescent migraine population.
S2WA4002 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy Of Oral Naratriptan (2.5mg) For The Treatment Of Migraine In Subjects Who Do Not Respond To Oral Sumatriptan (50mg)
S2WA4003 Completed A Randomized, Double-Blind, Double-Dummy, Active-Placebo Controlled, Parallel Group Evaluation of Oral Naratriptan (2.5mg) Compared to Oral Naproxen Sodium (275mg) on Migraine-Related Quality of Life.
S2WA4004 Completed A Randomized, Double-Blind, Double-Dummy, Active-Placebo Controlled, Parallel Group Evaluation of Oral Naratriptan (2.5mg) Compared to Oral Naproxen Sodium (275mg) on Migraine-Related Quality of Life.
S2WA4005 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of Oral Naratriptan (2.5mg) Administered Twice Daily in the Treatment of Transformed Migraine.
S2WA4006 Completed A randomized, double-blind, placebo-controlled, parallel group evaluation of oral naratriptan 1mg and 2.5mg twice daily as prophylactic treatment for menstrually-associated migraine.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.